Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2022
Innoviva announces FDA acceptance and priority review of new drug application for sulbactam-durlobactam
30 November 2022 - Sulbactam-durlobactam is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii, ...
Posted by Michael Wonder on 30 Nov 2022
European Commission grants expanded marketing authorisation for Gilead’s Biktarvy for the treatment of HIV in paediatric populations
29 November 2022 - European Commission authorises a low dose tablet for HIV treatment in virologically suppressed children at least two ...
Posted by Michael Wonder on 02 Nov 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis
2 November 2022 - NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
Evusheld receives Health Canada approval for treatment of COVID-19
18 October 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...
Posted by Michael Wonder on 07 Oct 2022
COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
Posted by Michael Wonder on 04 Oct 2022
Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement
4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...
Posted by Michael Wonder on 29 Sep 2022
Why non-funding of cystic fibrosis treatment is unacceptable
30 September 2022 - Edward Lee has self-funded the Trikafta drug that alleviates the symptoms of his cystic fibrosis since 2019. ...
Posted by Michael Wonder on 29 Sep 2022
FDA approves new treatment option for patients with ALS
29 September 2022 - The US FDA today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis, commonly ...
Posted by Michael Wonder on 25 Sep 2022
My brother is dying while there's a drug that could stop this
26 September 2022 - PHARMAC announced on Friday last week that Trikafta, a potentially life-saving drug for those suffering with ...
Posted by Michael Wonder on 24 Sep 2022
Bausch Health and Glenmark announce the approval of Ryaltris in Canada
23 September 2022 - Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis and associated ...
Posted by Michael Wonder on 20 Sep 2022
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
20 September 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...
Posted by Michael Wonder on 16 Sep 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19
16 September 2022 - Recommendation based on TACKLE Phase 3 treatment data showing reduced risk of severe COVID-19 or death. ...
Posted by Michael Wonder on 16 Sep 2022
PHARMAC can't progress cystic fibrosis drug Trikafta - CF New Zealand
16 September 2022 - PHARMAC is not in a position to progress funding on the life-extending cystic fibrosis drug, Trikafta, ...
Posted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...